Camp4 Therapeutics Corporation
CAMP•NASDAQ•Healthcare•Biotechnology

About Camp4 Therapeutics

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJoshua Mandel-Brehm
Founded2016
IPO DateOctober 11, 2024
Employees55
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.camp4tx.com
Phone617 651 8867
Address
One Kendall Square, 3rd Floor Cambridge, Massachusetts 02139 United States

Corporate Identifiers

CIK0001736730
CUSIP13463J101
ISINUS13463J1016
SIC2834

Leadership Team & Key Executives

Joshua Mandel-Brehm
Chief Executive Officer, President and Director
Dr. Richard A. Young Ph.D.
Founder and Independent Director
Kelly Gold
Chief Financial Officer
Dr. Yuri Maricich M.B.A., M.D.
Chief Medical Officer
Dr. Leonard I. Zon M.D.
Founder and Chairman of Scientific Advisory Board
Caleb Moore
Chief Business Operations Officer
Dr. Daniel Tardiff Ph.D.
Chief Scientific Officer
Michelle Gates
Senior Vice President and Chief People Officer
Dr. David Bumcrot Ph.D.
Senior Vice President of Research
Alla Sigova Ph.D.
Senior Vice President of Platform